Identification and characterization of a virus-specific continuous B-cell epitope on the PrM/M protein of Japanese Encephalitis Virus: potential application in the detection of antibodies to distinguish Japanese Encephalitis Virus infection from West Nile Virus and Dengue Virus infections by Hua, Rong-Hong et al.
RESEARCH Open Access
Identification and characterization of a virus-specific
continuousB-cellepitopeonthePrM/Mproteinof
JapaneseEncephalitisVirus:potentialapplicationin
thedetectionofantibodiestodistinguishJapanese
EncephalitisVirusinfectionfromWestNileVirusand
DengueVirusinfections
Rong-Hong Hua
1, Na-Sha Chen
1, Cheng-Feng Qin
2, Yong-Qiang Deng
2, Jin-Ying Ge
1, Xi-Jun Wang
1, Zu-Jian Qiao
1,
Wei-Ye Chen
1, Zhi-Yuan Wen
1, Wen-Xin Liu
1, Sen Hu
1, Zhi-Gao Bu
1*
Abstract
Background: Differential diagnose of Japanese encephalitis virus (JEV) infection from other flavivirus especially
West Nile virus (WNV) and Dengue virus (DV) infection was greatly hindered for the serological cross-reactive. Virus
specific epitopes could benefit for developing JEV specific antibodies detection methods. To identify the JEV
specific epitopes, we fully mapped and characterized the continuous B-cell epitope of the PrM/M protein of JEV.
Results: To map the epitopes on the PrM/M protein, we designed a set of 20 partially overlapping fragments
spanning the whole PrM, fused them with GST, and expressed them in an expression vector. Linear epitope M14
(
105VNKKEAWLDSTKATRY
120) was detected by enzyme-linked immunosorbent assay (ELISA). By removing amino acid
residues individually from the carboxy and amino terminal of peptide M14, we confirmed that the minimal unit of
the linear epitope of PrM/M was M14-13 (
108KEAWLDSTKAT
118). This epitope was highly conserved across different
JEV strains. Moreover, this epitope did not cross-react with WNV-positive and DENV-positive sera.
Conclusion: Epitope M14-13 was a JEV specific lineal B-cell epitpe. The results may provide a useful basis for the
development of epitope-based virus specific diagnostic clinical techniques.
Background
Japanese encephalitis virus (JEV) is the most important
cause of epidemic encephalitis in most Asian regions.
The virus belongs to the genus Flavivirus of the family
Flaviviridae; about 35,000-50,000 cases of and 10,000
deaths from JEV infection are reported annually [1]. JEV
was first isolated in Japan in 1935, following which it
spread to most other Asian countries. At present, this
v i r u si se v e nf o u n di nr e g i ons beyond its ecological
boundaries. Recently, JEV has spread to regions as far as
northern Australia [2,3]. Hence, there is a concern that
JEV might become a global threat. In fact, it is not unu-
sual to find 2 or more flaviviruses co-circulating in one
area. In Southeast Asia, the most important flaviviruses
are JEV and dengue viruses (DENV) [4]. In northern
Australia, Kunjin virus is found to co-circulate with JEV
[5]. In Vladivostok, Russia, studies have reported the
detection of WNV in birds [6]. In addition, there is evi-
dence that WNV infection in India from Japanese ence-
phalitis nonendemic areas and endemic areas [7].
The flaviviruses WNV, DENV, and JEV share some
common features, such as transmission via mosquitoes,
and cross-react with each other in serological tests.
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interpretation during serological testing, including neu-
tralization tests and enzyme-linked immunosorbent
assay (ELISA) [8]. JEV contains a single-stranded, posi-
tive-sense RNA genome with a size of 11 kb; the gen-
ome encodes 3 structural proteins, namely, core protein
(C), premembrane protein (prM/M), and envelope pro-
tein (E), and 7 nonstructural proteins (NS1, NS2A,
NS2B, NS3, NS4A, NS4B, NS5). Of the 10 proteins, the
E protein is the dominant antigen responsible for elicit-
ing neutralizing antibodies and plays an important role
in inducing immunologic responses in the infected host.
However, antibodies against the E proteins of the 3
aforementioned flaviviruses could cross-reactive with
each other. Previous reports [9,10] show that in western
blot (WB) prM protein may be used to serologically dif-
ferentiate individuals infected with JEV from those
infected with DENV, WNV and SLEV. Our preliminary
WB results for JEV-positive sera also showed that prM
reactivity could be used to differentiate JEV-positive
sera from WNV- and DENV-positive sera. Hence, prM
and antibodies against prM would be useful for con-
ducting seroepidemiological studies of flavivirus infec-
t i o n si nt h er e g i o n st h a th a v ep r e v a l e n c eo fm o r et h a n
one flavivirus. However, because prM is a membrane
protein, it is difficult to express it in Escherichia coli or
o t h e re x p r e s s i o ns y s t e m s .I nt h i sr e p o r t ,w em a p p e d
and identified a linear B-cell epitope on the prM/M
protein of JEV.
Results
Mapping of antigenic epitopes on PrM/M protein of JEV
To map the antigenic epitope of the JEV PrM/M pro-
tein, 20 partially overlapping 16-amino-acid long frag-
ments (M1-M20) were designed (M20 was 15-amino-
acid long) spanning the entire length of the PrM/M pro-
tein (Fig. 1A). All the fragments were fused with GST
and expressed in the pGEX-6p-1 vector. The recombi-
nant fusion proteins were purified with Glutathione
Sepharose 4B RediPack column affinity chromatography
according to the manufacturer’s instructions (Amer-
sham-Pharmacia Biotech) (Fig. 1B). Indirect ELISA and
western blot assays with pooled JEV-positive swine sera
were performed for antigenicity analysis of the 20
recombinant fusion proteins. Both ELISA (Fig. 2) and
western blot (data not shown) results revealed that the
peptide M14 was recognized by the JEV-positive swine
sera.
Epitope M14 was JEV specific
To investigate whether thea n t i - D E N Vo ra n t i - W N V
sera could recognize the M14 epitope, we synthesized
an epitope peptide VNKKEAWLDSTKATRY and used
it as coating antigen for indirect ELISA with anti-DENV
and anti-WNV sera. The result showed that epitope
M14 could only be recognized by anti-JEV sera but not
by anti-DENV and anti-WNV sera (Fig. 3).
The epitope M14-specific MAb 2F7 was generated by
using epitope fusion protein GST-M14 as the antigen
for immunofluroscence assay and synthesized epitope
M14 peptide as the antigen for indirect ELISA. To
investigate whether the MAb 2F7 could recognize the
native PrM/M protein in infected cells, we stained the
infected BHK-21 cells with the MAb 2F7. We found
that MAb 2F7 could stain JEV-virus infected cells but
not uninfected cells (Fig. 4A, 4B). Moreover, in the wes-
tern blot analysis, the MAb 2F7 antibody recognized a
19-kd PrM/M band (data not shown). These results
demonstrated that the linear continuous epitope M14
was expressed on the surface of JEV. Both Western blot
and immunofluorescence assays revealed that the epi-
t o p e - s p e c i f i cM A br e c o g n i z e dt h en a t i v eP r M / M
protein.
Fine mapping of the epitope
To precisely locate the core sequence of epitope M14 on
the PrM/M protein, a series of truncated peptides were
designed and expressed after fusion with GST. First, the
amino acid residues were removed one by one from the
carboxy terminal of peptide M14 until the peptide was
only 6-amino-acid long. The shortened peptide fusion
protein was analyzed by ELISA using MAb 2F7. The
result showed that when 3 or more amino acid residues
were removed, the reactivity between MAb 2F7 and
peptide fusion protein decreased completely (Fig. 5).
Next, the amino acid residues were removed one by one
from the amino terminal of peptide M14-2 until the
peptide was only 6-amino-acid long. The shortened pep-
tide fusion proteins were also analyzed by ELISA using
MAb 2F7. We found that when 4 or more amino acid
residues were removed from the amino terminal, the
reactivity between MAb 2F7 and the peptide fusion pro-
tein decreased greatly. Taken together, these results
demonstrated that peptide M14-13 (KEAWLDSTKAT)
is the minimal requirement for MAb 2F7 to recognize
the linearized epitope.
Homology and cross-reactivity analysis
To analyze the homology among the linear PrM/M pro-
tein epitopes, we used the PrM/M protein sequences
from 24 different JEV strains for alignment analysis. Of
t h e2 4J E Vs t r a i n s ,a l lg e n o t y p e4J E Vw e r ei n c l u d e d .
The alignment analysis revealed that the sequence of
the linear epitope is greatly conserved across the JEV
strains, except in the JKT6468 strain that had a muta-
tion (D to N) (Fig. 6). In fact, the further survey showed
that the substitution at this amino acid residue did not
affect the binding ability of MAb 2F7 to the epitope.
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Page 2 of 8Sequence alignment was also performed between the
epitope and the homologous sequences of other 2 flavi-
viruses, i.e., WNV and DENV (Fig. 7A). The homology
between epitope M14-13 and those from the 4 serotype
D E N Vw a sl e s st h a n4 0 % .T h eh o m o l o g yb e t w e e ne p i -
tope M14-13 and WNV (including 2 lineages) was more
than 80%. After the homologous sequences of WNV
were fusion expressed with GST, none of the sequences
showed reactivity with JEV-positive swine sera (Fig. 7C)
by ELISA. And for MAb only peptide lineage II strain
956 WNV showed weakly reactive with MAb 2F7 and
epetide lineage I strain NY99 did not reactive with MAb
2F7 (Fig. 7B).
Discussion
In this study, a series of overlapping 16-amino-acid long
peptides spanning the whole PrM/M protein of JEV were
fused expressed with GST. Using the GST fusion protein
set and the pooled JEV-positive swine sera, we mapped
the linear epitope of the JEV PrM/M protein. The ELISA
results indicated that the epitope was located in the M14
region (
105VNKKEAWLDSTKATRY
120). Moreover, by
individually removing amino acid residues from the car-
boxy and amino terminals of the peptide M14, we con-
firmed that the minimal unit of the linear epitope of
PrM/M was M14-13 (
108KEAWLDSTKAT
118). Sequence
alignment showed that the epitope was greatly conserved
Figure 1 Short peptide designing, expression and purification. (A) Schematic diagram of the relative location of the truncated prM/M
protein fragments and overlapping short peptides, M1-M20, spanning the prM/M protein. The numbers in parentheses indicate the amino acids
located at the beginning or the end of each fragment. M1 to M20 are a set of partially overlapping short peptides covering the whole prM/M
protein of JEV. (B) Expression and purification of recombinant peptide fusion proteins. For each peptide a fusion expression recombinant plasmid
was constructed and transformed into host cell E. coli BL21 (DE3). After the cells were induced with IPTG, the supernatants of the sonicates were
purified by affinity chromatography. The purified proteins were analyzed by 12% SDS-PAGE and stained with Coomassie brilliant blue. M stands
for the protein molecular standards as labeled on the left.
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Page 3 of 8across different JEV strains. Of the 24 selected JEV
strains, only 1, i.e., strain JKT6468–a genotype 4 JEV
strain–has one amino acid residue (
113N) different from
that of the epitope M14-13 (
113D). However, further ana-
lysis revealed that this amino acid residue replacement
(
113Dt o
113N) did not affect the reactivity of the epitope
to MAb 2F7- and JEV-positive swine sera.
Cross-reactivity among flaviviruses has been a great
diagnostic challenge, especially for members of the JE
serocomplex, in which it is difficult to differentiate
between the strains by using ELISA or even by neutrali-
zation tests or other serological methods [11,12]. Serolo-
gical cross-reactivity was mainly observed because these
virus antigens contain the same immunodominant E gly-
coprotein epitopes responsible for eliciting a large pro-
portion of cross-reactive serum antibodies during viral
infection [13]. In this study, we identified a linear epi-
tope from the PrM/M protein; this epitope could react
with the JEV-positive swine sera and rabbit sera but not
with rabbit anti-DENV and anti-WNV sera. The homo-
geneity between this linear epitope and all 4 serotype
DENV PrM/M protein was less than 40%. Moreover,
the same domains of the PrM/M protein from WNV
did not react with the swine-anti JEV sera. and MAb
2F7. And only peptide lineage II strain 956 WNV
showed weakly reactive with MAb 2F7 and epetide line-
age I strain NY99 did not reactive with MAb 2F7. How-
ever around the world the predominant WNV were
lineage I and lineage II consists exclusively of viruses
from southern Africa and Madagascar and rare Europe
district [14]. Hence, we confirmed that the epitope
M14-13 was virus specific and could be potentially used
in serological monitoring and for differential diagnosis
of JEV infection.
Epitope identification was useful for elucidating the
antigenic characteristics of the prM protein. The epi-
topes on E protein [15] and NS1 protein [16] of JEV
have been mapped. However, thus far, the epitope on
the PrM/M protein of JEV has not been mapped. Here,
Figure 2 Identification of the antigenic determinants on the prM/M protein with JEV-positive swine sera. (A) ELISA analysis of the short
fusion peptides. Microtiter plates were coated with purified recombinant fusion protein samples (2 μg/100 μl per well). The plate was blocked
with skim milk and pooled JEV-positive swine sera (dilution, 1:200) was added, following which HRP-coupled goat anti-pig IgG secondary
antibody was added. Only peptide M14 showed strong reactivity with the JEV-positive swine sera. (B) Western blot analysis confirmed the result
of ELISA. JEV-positive swine sera could react with GST-M14 but not with other peptide fusion protein and GST.
Figure 3 The epitope did not react with WNV-positive and
DENV-positive sera. The synthesized epitope peptide was used as
coating antigen in indirect ELISA. The reactivity of the epitope with
the rabbit sera against JEV and that of the rabbit sera against DENV
were assessed. Rabbit sera against JEV and normal rabbit sera were
used as the positive and negative controls, respectively.
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Page 4 of 8Figure 4 Immunofluorescence analysis of epitope-specific mice monoclonal antibody 2F7. Immunofluorescence assay of the harvested
and fixed BHK21 cells infected with JEV with epitope-specific MAb 2F7 as the primary antibody and a FITC-conjugated goat anti-mouse IgG as
the secondary antibody revealed that MAb recognized JEV infected BHK21 cells (A) but not uninfected cells (B).
Figure 5 Finer mapping the epitope M14-13. Peptide M14 was truncated from the carboxy and amino terminal. After short protein fragments
were fusion expressed with GST, they were analyzed by ELIZA using MAb 2F7. When 2 or more amino acid residues were removed from the
carboxy terminal and 4 or more amino acid residues were removed form the amino terminal, the reactivity between MAb 2F7 and peptide
fusion protein decreased greatly. This result shows that peptide M14-13 (KEAWLDSTKAT) is the minimal requirement for MAb 2F7 to recognize
the linearized epitope.
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Page 5 of 8we first mapped the epitope on the PrM/M protein and
identified a JEV-specific and highly conserved linear
B-cell epitope precisely on the JEV PrM/M protein. It
becomes difficult to purify and express membrane pro-
teins in E. coli. However, the epitope on the JEV PrM/
M protein can be easily fusion expressed with a vector
protein or can be coupled with a vector protein after
synthesis. This is the first report on the generation of
MAbs against the PrM/M protein using epitope fusion
as the immune antigen.
Conclusions
T h ep r e s e n ts t u d yf u l l ym a p p e dt h el i n e a le i p t o p eo n
PrM/M protein of JEV and identified one lineal B-cell
epitope M14-13. The epitope M14-13 was JEV specific
and highly conservec among different JEV strains.
These data could provide important basis for the
potential application of epitope-based virus-specific
diagnosis and would also be useful for further elucidating
antigenic structure and biological function of PrM/M
of JEV.
Methods
Cell lines, viruses, and serum specimens
Baby hamster kidney (BHK-21) cells and SP2/0 mye-
loma cells were cultured in RPMI-1640 medium
supplemented with 10% fetal calf serum and antibio-
tics. All the cells were maintained in humidified 5%
CO2 atmosphere at 37°C. The JEV strain SA14-14-2
[GenBank: AF315119] was propagated in BHK-21 cells
to prepare the antigen for WB and immunofluores-
cence assays. The JEV-positive sera were obtained
from pigs reared in pig farms. The sera were first
tested by indirect ELISA and latex agglutination test
(LAT) for detecting antibodies to JEV. Hyperimmune
sera against JEV, WNV, and DENV were obtained
from rabbits that had been inoculated with purified
JEV, WNV, and DENV, respectively.
Expression and purification of overlapping short
fragments covering the PrM/M protein
To map the epitope on the PrM/M protein of JEV, we
designed a set of 20 partially overlapping short pep-
tides M1-M20 covering the whole PrM/M protein as
shown in fig 1A. For each short peptide, a pair of oli-
gonucleotide strands was synthesized. The 2 strands
were annealed, and the resultant double-stranded DNA
contained a BamHI and an XhoI cohesive terminus at
the 5’ and 3’ ends, respectively. The annealed fragment
was cloned into the expression vector pGEX-6p-1. The
inserts in the recombinant plasmids were sequenced,
and the confirmed recombinant plasmids were
Figure 6 Sequence alignment of the epitope M14-13 with different JEV strains. Full-length sequences of 23 different JEV strains were
selected from the GenBank. GenBank accession numbers are listed in the parentheses. Epitope M14-13 was highly conserved across these JEV
strains.
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Page 6 of 8transformed into E. coli strain BL21 and induced with
0.1 M isopropyl-D-thiogalactopyranoside (IPTG) at 37°C
for 4 h. The expressed recombinant fusion proteins
were analyzed with sodium dodecyl sulfate (SDS)-poly-
acrylamide gel electrophoresis (PAGE). Next, the
fusion proteins were purified by Glutathione Sepharose
4B RediPack Column affinity chromatography accord-
ing to the manufacturer’s instructions (Amersham
Pharmacia Biotech). Subsequently, the bound fusion
protein was eluted with glutathione elution buffer (10
mM reduced glutathione, 50 mM Tris-HCl, pH 8.0)
for further analysis.
Enzyme-linked immunosorbent assay (ELISA)
Ninety-six-well microtiter plates were coated with puri-
fied fusion protein or denatured inclusion body in 0.1 M
carbonate buffer (pH 9.6) at 4°C overnight and blocked
with 5% skim milk for 3 h. Subsequently, the plates
were washed 3 times with PBST (phosphate buffered
saline, PBS with 0.1% Tween 20). In the binding assay,
the plates were incubated with diluted rabbit hyperim-
mune sera or swine sera at 37°C for 1 h followed by
washing 3 times with PBST. Bound antibodies were
detected with horseradish peroxidase (HRP)-conjugated
secondary antibody. The reaction was stopped with 2 M
H2SO4, and the absorbance was measured at 450 nm by
using a microplate autoreader (Bio-Rad). In peptide
ELISA, microtiter plates were coated with the synthe-
sized peptide.
Western blotting
Virus-infected cell lysates or expressed fusion proteins
were mixed with an equal volume of sample loading
buffer (50 mM Tris-HCl, pH 6.8; 100 mM dithiothretol
(DTT); 2% SDS; 0.1% bromophenol blue; and 10%
glycerol) and separated by 12% SDS-PAGE. For immu-
noblotting, the proteins were transferred from the
SDS-polyacrylamide gel to a nitrocellulose membrane.
Non-specific antibody binding sites were blocked with
5% skim milk in PBS overnight at 4°C. The membranes
were incubated with primary antibody at 37°C for 1 h
and then washed 3 times with PBST (10 min each time).
Next, the blot was probed with an appropriate second-
ary antibody (1:5,000) for 1 h at 37°C. The following
Figure 7 Specificity analysis of the epitope. (A) Sequence alignment between the identified linear epitope and the homologous regions of
WNV and DENV. The virus strains listed in this figure were selected as representative strains. Abbreviations of each virus and GenBank accession
numbers are listed in the parentheses. (B, C) The epitope homology peptides of WNV were expressed and analyzed by ELISA using MAb 2F7.
The homology peptide of WNV strain NY99 did not react with MAb 2F7, while the homology peptide of WNV strain 956 was weakly reactive
with MAb 2F7 (B). JEV-positive swine sera also did not reactive with the homology peptide of WNV (C).
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Page 7 of 8secondary antibodies were used: horse radish peroxidase
(HRP)-conjugated goat anti-mouse IgG (Sigma) and
HRP-conjugated goat anti-pig IgG (Beijing Zhongshang
biotechnology Co., Ltd.). After incubation with the sec-
ondary antibody, each blot was washed 3 times with
PBST, and then developed with HRP developer.
Generation of monoclonal antibody (MAb)
BALB/c mice were immunized with 250 μg epitope
fusion protein GST-M14 in 0.5 ml emulsion with com-
plete Freund’s adjuvant. At 2 weeks interval, 2 booster
injections with the same dose of emulsion were adminis-
tered as the first immunization. At 3 days after the last
injection, the spleens were surgically removed from the
mice. Splenocytes were fused with SP2/0 myeloma cells
as described previously [17]. Hybridoma clones were
screened by indirect ELISA using synthesized epitope
peptides M14 as the coating antigen. Selected clones
were subcloned by limiting dilution. The resultant hybri-
doma clones were isotyped using an isotyping kit from
Roche Diagnostics. Ascites fluids were produced in pris-
tine-primed BALB/c mice.
Immunofluorescence assays
BHK-21 cells were infected with JEV strain SA14-14-2
and incubated for 72 h at 37°C. The cells were harvested
by scraping, centrifuged, and washed twice in PBS. Glass
slides were coated with the infected cells, air-dried, and
fixed with acetone. In the immunofluorescence assays,
epitope-specific MAb and fluorescein isothiocyanate
(FITC)-conjugated goat anti-mouse IgG (Jackson IR)
were used as the primary and secondary antibodies,
respectively. The samples were analyzed by using a
Leica microscope, and the images were acquired with a
Leica digital camera.
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